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Abstract
Objective:  To  identify  pathogenic  genomic  imbalances  in  patients  presenting  congenital  heart
disease (CHD)  with  extra  cardiac  anomalies  and  exclusion  of  22q11.2  deletion  syndrome
(22q11.2 DS).
Methods:  78  patients  negative  for  the  22q11.2  deletion,  previously  screened  by  fluorescence
in situ  hybridization  (FISH)  and/or  multiplex  ligation  probe  amplification  (MLPA)  were  tested  by
chromosomal  microarray  analysis  (CMA).
Results:  Clinically  significant  copy  number  variations  (CNVs  ≥300  kb)  were  identified  in  10%
(8/78) of  cases.  In  addition,  potentially  relevant  CNVs  were  detected  in  two  cases  (993  kb
duplication  in  15q21.1  and  706  kb  duplication  in  2p22.3).  Genes  inside  the  CNV  regions  found
in this  study,  such  as  IRX4,  BMPR1A,  SORBS2,  ID2,  ROCK2,  E2F6,  GATA4,  SOX7,  SEMAD6D,  FBN1,
and LTPB1  are  known  to  participate  in  cardiac  development  and  could  be  candidate  genes  for
CHD.
Conclusion:  These  data  showed  that  patients  presenting  CHD  with  extra  cardiac  anomalies  and
exclusion  of  22q11.2  DS  should  be  investigated  by  CMA.  The  present  study  emphasizes  the
possible role  of  CNVs  in  CHD.
© 2017  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  This  is  an  open
access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/
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Desequilíbrios  genômicos  na  cardiopatia  congênita  sindrômica
Resumo
Objetivo:  Identificar  desequilíbrios  genômicos  patogênicos  em  pacientes  apresentando  Car-
diopatias  Congênitas  (CC)  e  anomalias  extra  cardíacas,  e  exclusão  da  Síndrome  de  Delec¸ão
22q11.2 (SD22q11.2).
Métodos:  Um  total  de  78  pacientes  negativos  para  a  delec¸ão  22q11.2,  previamente  testados  por
hibridac¸ão in  situ  com  fluorescência  (FISH)  e/ou  amplificac¸ão  de  múltiplas  sondas  dependentes
de ligac¸ão  (MLPA),  foram  avaliados  por  microarray  cromossômico  (CMA).
Resultados:  Foram  identificadas  variac¸ões  do  número  de  cópias  de  DNA  (CNVs)  clinicamente
significativas  (≥  300  kb)  em  10%  (8/78)  dos  casos,  além  de  CNVs  potencialmente  relevantes
em dois  casos  (duplicac¸ão  de  993  kb  em  15q21.1  e  duplicac¸ão  de  706  kb  em  2p22.3).  Genes
envolvidos como  IRX4,  BMPR1A,  SORBS2,  ID2,  ROCK2,  E2F6,  GATA4,  SOX7,  SEMAD6D,  FBN1  e
LTPB1 são  conhecidos  por  atuarem  no  desenvolvimento  cardíaco  e  podem  ser  genes  candidatos
a CC.
Conclusão:  Estes  dados  mostram  que  pacientes  apresentando  CC,  com  anomalias  extra  cardía-
cas e  exclusão  da  SD22q11.2,  devem  ser  investigados  por  CMA.  Ainda,  este  estudo  enfatiza  a
possível func¸ão  das  CNVs  nas  CC.
© 2017  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Este e´ um  artigo
Open Access  sob  uma  licenc¸a  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.
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ongenital  heart  disease  (CHD)  is  a  common  malformation
ffecting  approximately  six  per  1000  live  births.  It  occurs  as
n  isolated  trait  or  related  to  multiple  congenital  anoma-
ies,  among  which  the  22q11.2  deletion  syndrome  (22q11.2
S)  is  the  most  common.1 CHD  is  the  most  critical  mani-
estation  and  represents  the  major  morbimortality  factor
n  22q11.2  DS,  affecting  between  74%  and  80%  of  patients.
mong  the  variety  of  CHDs  reported,  conotruncal  and/or
ortic  arch  defects  are  the  most  prevalent.2 The  cause  of
ardiac  phenotypic  heterogeneity  is  not  known,  but  there  is
o  evidence  of  correlation  with  sex,  race,  22q11.2  deletion
ize,  or  parental  origin  of  the  deletion.3
It  is  recommended  that  all  newborns  or  children  present-
ng  CHD  and  dysmorphism  or  other  congenital  anomalies  be
creened  for  22q11.2  deletion.4 In  addition,  genomic  imbal-
nces  of  other  chromosomal  regions,  including  10p12-p15,
q21-q35,  8p21-p23,  17p13,  and  18q21,  can  be  found  in
atients  with  clinical  suspicion  of  22q11.2  DS  and  without
2q11.2  deletion.5
Currently,  the  application  of  chromosomal  microarray
nalysis  (CMA)  for  clinical  diagnosis  allows  the  identifica-
ion  of  previously  undetectable  submicroscopic  genomic
mbalances,  bringing  new  information  about  the  genesis  of
ongenital  defects.  The  current  study  investigated  a group
f  individuals  presenting  CHD  with  extra  cardiac  anomalies
nd  exclusion  of  22q11.2  DS  to  identify  pathogenic  genomic
mbalances.
atients and  methods
atientshe  Research  Ethics  Committee  of  the  University  of  Camp-
nas  approved  this  study  (No.  487/2009  and  433/2010).  All
articipants  or  their  guardians  signed  the  written  informed
t
e
p
aonsent.  The  evaluation  included  a  standardized  protocol
s  part  of  a  multicenter  study  of  the  Brazilian  Craniofacial
roject,  and  all  individuals  were  seen  by  a  geneticist.
Initially,  a  group  of  108  patients  having  CHD  with  extra
ardiac  anomalies  and  clinical  suspicion  of  22q11.2  deletion
ere  screened  by  fluorescence  in  situ  hybridization  (FISH)
nd/or  multiplex  ligation  probe  amplification  (MLPA).  Only
8  patients  (43  males  and  35  females)  without  22q11.2  dele-
ion  were  included  in  the  present  study.
Among  the  CHDs  in  this  cohort,  tetralogy  of  Fallot  (ToF)
as  observed  in  40%,  ventricular  septal  defect  (VSD)  in  22%,
nd  atrial  septal  defect  (ASD)  in  8%  of  cases.  In  9%  of  cases,
wo  of  these  three  defects  were  observed.  The  remaining
1%  of  cases  presented  other  cardiac  defects  such  as  trun-
us  arteriosus  (TA),  bicuspid  aortic  valve  (BAV),  and  patent
uctus  arteriosus  (PDA),  among  others.
The  main  clinical  features  found  in  these  patients,  in
ddition  to  CHD,  were:  facial  dysmorphisms  --  96%  (75/78),
eurocognitive  and  behavioral-developmental  abnormali-
ies  --  65%  (51/78),  skeletal  abnormalities  --  58%  (45/78),
alatal  abnormalities  --  43%  (34/78),  immunological  abnor-
alities  --  41%  (32/78),  growth  delay  and/or  feeding
bnormalities  --  32%  (25/78),  gastrointestinal  anomalies  --
3%  (18/78),  hearing  loss  --  10%  (8/78),  urinary  tract  anoma-
ies  --  10%  (8/78),  eye  abnormalities  --  9%  (7/78),  and
eurological  abnormalities  --  5%  (4/78).
ethods
hromosomal  microarray  analyses  were  performed  for  all
8  patients.  Patient’s  parents  were  not  tested.  For  each
ample,  250  ng  of  genomic  DNA  was  labeled  and  hybridized
o  the  CytoScan  HD  chip  (Affymetrix
®
,  USA),  according  tohe  recommendations  of  the  manufacturer.  QC  metrics  were
valuated  with  the  Affymetrix
®
genotyping  console  software
ackage.  Array  data  were  analyzed  using  a  chromosome
nalysis  suite  (ChAS;  Affymetrix
®
).  Filters  of  25  genetic
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108 patients
Tested by FISH
and/or MLPA
30 patients positive for
22q11.2 deletion
78 patients negative for
22q11.2 deletion
Screened by CMA
(Affymetrix)
CNVs detected by ChAS
(Affymetrix)
≥ 300 kb
Confirmed by nexus
copy number
Confirmed by comparing
with a brazilian internal
control (FCM-Unicamp)
YesYes
Relevant CNVs
Tested by CMA (Agilent)
for confirmation
Searched in: DGV, DECIPHER and OMIM
Excluded from this study
Figure  1  Flow  chart  of  the  patient  population  and  the  techniques  applied.  FISH,  fluorescence  in  situ  hybridization;  MLPA,  multiplex
Vs,  c
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pligation probe  amplification;  CMA,  chromosomal  microarray;  CN
database of  genomic  variants;  DECIPHER,  database  of  chromoso
OMIM, Online  Mendelian  Inheritance  In  Man.
markers  for  deletion  and  50  for  duplications  were  applied,
as  recommended  by  the  manufacturer,  and  a  minimum  seg-
ment  length  of  300  kb  for  both  duplications  and  deletions
was  also  applied  (defined  as  large  copy  number  variations
--  CNVs).  These  CNVs  were  confirmed  using  the  Nexus  Copy
Number  software  (BioDiscovery
®
,  USA).  CNVs  were  further
compared  with  an  internal  control  CNV  dataset,  including
105  controls  from  the  Brazilian  general  population,  designed
by  using  Cytoscan  HD  (Affymetrix
®
).  Only  genomic  imbal-
ances  found  by  all  the  approaches  were  selected  for  further
investigation,  using  the  following  databases:  the  Database
of  Genomic  Variants  (DGV),6 the  Database  of  Chromoso-
mal  Imbalance  and  Phenotype  in  Humans  using  Ensembl
Resources  (DECIPHER),7 and  the  Online  Mendelian  Inher-
itance  in  Man  (OMIM).8 CNVs  considered  relevant  were
carried  forward  to  confirmation  by  another  microarray  plat-
form.  This  confirmation  was  performed  for  18  patients  using
the  Agilent  human  genome  G3  SurePrint  8x60K  microarray
(Agilent  Technologies®,  USA).  DNA  extracted  from  patients
R
A
dopy  number  variations;  ChAS,  chromosome  analysis  suite;  DGV,
mbalance  and  phenotype  in  humans  using  ensemble  resources;
nd  reference  controls  (Promega®,  USA)  were  measured  for
oncentration  and  purity  with  a  Qubit
®
spectrophotome-
er  (Life  Technologies®,  USA).  The  quantity  of  500  ng  of
NA  from  the  patient  and  of  a  sex-matched  reference  DNA
ere  processed  for  labeling  and  hybridization  according  to
he  manufacturer’s  protocol  (Agilent  oligonucleotide  array-
ased  CGH  for  genomic  DNA  analysis  --  Enzymatic  labeling
rotocol  v.7.3).  Slides  were  scanned  in  a  dual-laser  scanner
4900DA  (Agilent  Technologies®,  USA)  and  the  images  were
xtracted  and  analyzed  by  using  Agilent  feature  extraction
oftware  (v.11.5.1.1).  Array  data  were  analyzed  using  Agi-
ent  cytogenomics  software  (v.3.0.1.1).  A  flow  chart  with  the
atient  population  that  was  studied  is  summarized  in  Fig.  1.esults
 total  of  67  CNVs  ≥300  kb  were  detected,  comprising  33
eletions  and  34  duplications.  CNVs  with  less  than  100%  of
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verlap  of  DECIPHER  cases  and  CNVs  with  more  than  four
ccurrences  in  the  DGV  (overlapping  more  than  50%)  were
ot  considered  potentially  relevant.
Among  67  CNVs  ≥300  kb,  25  encompassed  genes;  11  dele-
ions  and  14  duplications.  Eighteen  CNVs  were  confirmed
y  another  microarray  platform  and  two  had  been  previ-
usly  detected  by  FISH  and/or  MLPA  techniques  (Table  1).
yndromes  of  multiple  congenital  anomalies  have  already
een  reported  in  the  literature  involving  eight  of  these
NVs:  16p11.2  deletion  syndrome  OMIM  611913  (case  8),
7q12  deletion  syndrome  OMIM  614527  (case  26),  5p  deletion
yndrome  OMIM  123450  (case  29),  3q  duplication  syndrome
case  40),  10q22-q23  deletion  syndrome  OMIM  612242  (case
1),  4q  deletion  syndrome  (case  72),  8p23.1  deletion  syn-
rome  (case  77),  and  22q13.33  deletion  syndrome  OMIM
06232  (case  78).  These  patients  had  clinical  features  that
verlap  with  22q11.2  DS  (Table  2).
Therefore,  pathogenic  CNVs  were  detected  in  eight  out  of
8  patients  (10%),  with  sizes  from  611  kb  to  17.4  Mb.  Genes
ecognized  to  participate  in  cardiac  development  and  can-
idate  genes  for  CHD  are  reported  in  Table  3.  In  addition,
wo  potentially  relevant  CNVs  encompassing  cardiac  genes
ere  identified  (993  kb  duplication  in  15q21.1  and  706  kb
uplication  in  2p22.3).
iscussion
lucidating  the  genetic  contribution  of  complex  disorders
s  difficult  due  to  the  large  number,  low  frequency,  and
ariable  effect  of  predisposition  loci. Genomic  CNVs  have
een  established  as  a  major  source  of  human  genetic
ariation  underlying  several  multiple  congenital  anomaly
yndromes,  including  22q11.2  DS.  Determining  whether  a
NV  contributes  to  a  phenotype  depends  on  various  fac-
ors,  including  the  mode  of  inheritance,  gene  content,  the
opy  number  state  (a  loss  or  a  gain),  the  array  platform
sed,  and  if  it  was  found  in  controls  from  the  general
opulation.9 In  general,  larger  CNVs  have  a  higher  potential
f  being  pathogenic,  as  it  is  more  possible  that  a  dosage-
ensitive  gene  is  involved,  and/or  a  larger  number  of  genes
re  included  in  the  imbalance,  resulting  in  an  abnormal
henotype.10
The  classification  of  a  CNV  not  reported  before,  and  not
ncluding  a  previously  known  disease  gene,  can  vary  between
ifferent  populations.10 Therefore,  the  present  CNV  analy-
is  was  conducted  focusing  on  diagnosis  and  according  to
hree  analytical  approaches,  as  there  is  not  a  Brazilian  con-
rol  population  database  available  yet.  A  minimum  size  of
00  kb  was  considered  (defined  as  large  CNVs),  the  number
f  genetic  markers  recommended,  and  only  CNVs  identi-
ed  by  all  three  approaches  were  selected  for  research  and
onfirmation.
Pathogenic  CNVs  were  detected  in  eight  out  of  78  patients
10%)  and  genes  involved  such  as  IRX4,  BMPR1A,  SORBS2,
D2,  ROCK2,  E2F6,  GATA4,  and  SOX7  are  known  to  participate
n  cardiac  development  and  would  be  candidate  genes  for
HD.11--18Case  8  showed  a  611  kb  deletion  overlapping  the  crit-
cal  region  of  16p11.2  deletion  syndrome.  Patients  with
his  syndrome  usually  present  developmental  delay,  intel-
ectual  disability,  features  of  autism  spectrum  disorders,
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eizures  (epilepsy),  and  obesity,19 not  presented  in  this
atient.  Less  frequently,  CHD,  minor  facial  dysmorphisms,
nd  speech  delay  were  observed,19 in  concordance  with
his  patient.  This  patient  had  ToF  and  interrupted  aortic
rch.  This  deleted  region  does  not  allocate  candidate  genes
elated  to  CHD,  to  date.
Case  26  showed  a  1.8  Mb  deletion  overlapping  the  critical
egion  of  17q12  deletion  syndrome.  Deletions  of  this  region,
ncluding  the  HNF1  ˇ gene,  have  been  found  in  patients  with
aturity-onset  diabetes  of  the  young  type  5  (MODY5),  and  in
atients  with  cystic  renal  disease,  renal  dilations,  pancre-
tic  atrophy,  and  liver  abnormalities,20 not  present  in  this
atient.  Recently,  intellectual  disability,  speech  delay,  and
acial  dysmorphisms  were  associated  with  this  deletion,21 in
ommon  with  this  patient,  but  CHD  has  been  not  mentioned.
his  patient  had  BAV.  There  are  no  candidates  genes  related
o  CHD  reported  in  this  deleted  region,  to  date.
Case  29  presented  a  17.4  Mb  deletion  in  5p15.1-p15.33,
arboring  the  5p  deletion  syndrome  (cri  du  chat  syndrome).
nfants  with  this  condition  often  have  a  high-pitched  cry  that
ounds  like  that  of  a  kitten,  microcephaly,  low  birth  weight,
nd  hypotonia,22 not  reported  by  patient’s  parents  (evalu-
ted  with  1  year).  Affected  individuals  also  have  intellectual
isability  and  developmental  delay,  distinctive  facial  fea-
ures,  including  hypertelorism,  low-set  ears,  small  jaw,  and
HD,22 as  observed  in  the  present  patient.  The  low  resolu-
ion  of  the  previous  karyotype  [46,XY]  hindered  the  diagnosis
f  this  patient,  which  was  improved  using  aGH.  The  patient
resents  PDA.  The  deleted  region  allocates  a cardiac  tran-
cription  factor  gene,  IRX4, in  which  mutations  were  related
o  CHD.11
Case  40  presented  a  2  Mb  duplication  in  3q26.2,  not
arboring  the  critical  region  of  3q  duplication  syndrome
defined  as  3q26.31-q27.3).  Recently,  cases  with  partial
q  duplications  involving  the  region  of  this  CNV  have
een  reported  and  associated  with  this  syndrome.23 The
henotype  usually  involves  CHD,  brain  abnormalities,  micro-
ephaly,  and  atypical  facial  dysmorphisms  in  common  with
his  patient.  The  patient  had  ToF,  ASD,  pulmonary  atresia,
nd  persistent  left  superior  vena  cava.  There  are  no  candi-
ate  genes  related  to  CHD  reported  in  this  duplicated  region,
o  date.
Case  71  showed  a  7.8  Mb  deletion  in  10q22.3-q23.2;  this
egion  was  recently  associated  with  a  new  syndrome  charac-
erized  by  behavioral  and  neurodevelopmental  impairment,
ncluding  cognitive  delay,  autism,  hyperactivity,  and  psychi-
tric  ilness.24 This  patient  presented  only  developmental
elay.  In  addition,  mild  facial  dysmorphisms  and  CHD  were
bserved  less  frequently  in  10q22-q23  deletion  syndrome,25
oth  present  in  this  patient.  The  patient  had  ToF.  This
eleted  region  harbors  the  BMPR1A  gene,  suggested  as  a
andidate  gene  for  CHD  because  of  its  role  in  embryonic
evelopment  and  heart  formation.12
Case  72  showed  a  4.5  Mb  deletion  in  4q35.1-q35.2.  Dele-
ions  in  4q  are  rare  and  are  associated  with  intellectual
isability,  craniofacial  dysmorphisms,  low-set  ears,  cleft
alate,  CHD,  and  fifth  finger  anomalies.26 This  patient  pre-
ented  most  of  these  characteristics,  with  exception  of
ow-set  ears  and  cleft  palate.  In  addition,  this  patient
howed  a  14.8  Mb  duplication  in  2p24.3-p25.3  and  a  375  kb
uplication  in  16p12.2,  both  CNVs  without  a  specific  phe-
otype  described  to  date.  The  patient  had  VSD,  ASD,
A
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Table  1  Type  of  CHD  and  CNVs  ≥  300  kb  observed  in  the  cohort.
ID  Type  of
CHD
CNV  Location  CNstate  Start  (bp) Stop  (bp) Size
(kb)
RefSeq  genes DGV  DECIPHER  Validated
by  aCGH
2  ASD  del  12p12.1-
p12.2
1  20,994,908  21,415,634  421  SLCO1B3,  SLCO1B7,  SLCO1B1 +  +  Yes
3 ASD  dup  15q22.2  3  62,209,640  62,543,660  334  VPS13C,  C2CD4A,  C2CD4B −  +  NP
8 ToF,  IAA del  16p11.2  1  29,567,295  30,177,916  611  SLC7A5P1,  SPN,  QPRT,  ZG16,  KIF22,  MAZ,
PRRT2,  MVP,  CDIPT,  SEZ6L2,  ASPHD1,  KCTD13,
TMEM219,  TAOK2,  HIRIP3,  INO80E,  DOC2A,
FAM57B,  ALDOA,  PPP4C,  TBX6,  YPEL3,  GDPD3,
MAPK3
+  +  Yes
13 TA dup  8p11.1-
p11.21
3  42,935,729  43,776,564  841  FNTA,  SGK196,  HGSNAT,  POTEA +  +  Yes
14 VSD,
ASD,  PA
del  10q25.1  1  110,420,129  111,116,531  696  RNU6-53,  MAPKAPK5P1-001  −  +  Yes
19 VSD  dup  Yp11.2 2  9,664,007  9,997,425  333  TTTY23,  TTTY23B −  +  NP
20 ASD,
PDA,  PA
dup  2q13  3  110,504,318  111,365,996  862  RGPD5,  RGPD6,  LIMS3,  LIMS3L,
LIMS3-LOC440895,  LOC440895,  LOC100288570,
LOC440894,  MIR4267,  MALL,  MIR4436B2,
MIR4436B1,  NPHP1,  LINC00116,  LOC100507334,
LOC151009
−  +  Yes
21 VSD  dup  7q21.13  3  88,819,024  89,678,695  860  ZNF804B  +  +  Yes
24 VSD,  TA,
PA
del  16p11.1-
p11.2
1  34,197,616  35,158,405  961  UBE2MP1,  LOC283914,  LOC146481,
LOC100130700,  RN5S411,  FLJ26245
−  −  Yes
26 BAV del  17q12  1  34,477,385  36,283,612  1806  TBC1D3B,  CCL3L3,  CCL3L1,  CCL4L2,  CCL4L1,
TBC1D3C,  TBC1D3H,  TBC1D3G,  ZNHIT3,
MYO19,  PIGW,  GGNBP2,  DHRS11,  MRM1,  LHX1,
AATF,  MIR2909,  ACACA,  C17orf78,  TADA2A,
DUSP14,  SYNRG,  DDX52,  HNF1B,  LOC284100
−  +  Yes
A
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Table  1  (Continued)
ID  Type  of
CHD
CNV  Location  CNstate  Start  (bp)  Stop  (bp)  Size
(kb)
RefSeq  genes  DGV  DECIPHER  Validated
by  aCGH
29  PDA  del  5p15.1-
p15.33
1  113,576  17,511,896  17,398  PLEKHG4B,  LRRC14B,  CCDC127,  SDHA,  PDCD6,
AHRR,  C5orf55,  EXOC3,  PP7080,  SLC9A3,
MIR4456,  CEP72,  TPPP,  ZDHHC11,  BRD9,  TRIP13,
LOC100506688,  NKD2,  SLC12A7,  MIR4635,
SLC6A19,  SLC6A18,  TERT,  MIR4457,  CLPTM1L,
SLC6A3,  LPCAT1,  SDHAP3,  LOC728613,  MIR4277,
MRPL36,  NDUFS6,  IRX4,  IRX2,  C5orf38,
LOC285577,  IRX1,  LOC340094,  ADAMTS16,
KIAA0947,  FLJ33360,  MED10,  UBE2QL1,
LOC255167,  NSUN2,  SRD5A1,  PAPD7,  MIR4278,
MIR4454,  LOC442132,  ADCY2,  C5orf49,  FASTKD3,
MTRR,  LOC729506,  LOC100505738,  MIR4458,
SEMA5A,  MIR4636,  LOC100505806,  SNORD123,
TAS2R1,  LOC285692,  FAM173B,  CCT5,  CMBL,
MARCH6,  ROPN1L,  ANKRD33B,  DAP,  CTNND2,  TAG,
DNAH5,  TRIO,  FAM105A,  FAM105B,  ANKH,
LOC100130744,  MIR4637,  FBXL7,  MARCH11,
ZNF622,  FAM134B,  MYO10,  LOC285696,  BASP1,
LOC401177
−  +  NP
30 ASD  dup  5q33.2  3  154,330,014  154,664,212  334  MRPL22,  KIF4B  −  −  NP
35 ToF,  PA,
PLSVC
dup  15q21.1  3  48,023,616  49,017,024  993  SEMA6D,  SLC24A5,  MYEF2,  CTXN2,  SLC12A1,  DUT,
FBN1
−  +  Yes
40 ToF,  PA,
ASD,
PLSVC
dup  3q26.2  3  168,485,398  170,468,489  1983  EGFEM1P,  MECOM,  TERC,  ACTRT3,  MYNN,  LRRC34,
LRRIQ4,  LRRC31,  SAMD7,  LOC100128164,  SEC62,
GPR160,  PHC3,  PRKCI,  SKIL,  CLDN11,  SLC7A14
−  +  Yes
52 ToF,  PA,
ASD
dup  2p22.3  3  32,628,617  33,334,307  706  BIRC6,  MIR558,  TTC27,  MIR4765,  LINC00486,
LOC100271832,  LTBP1
+  +  Yes
58 ToF,  PA  dup  6q14.3  3  87,387,316  87,921,049  534  HTR1E,  CGA,  ZNF292  -  +  Yes
59 ToF,  PA,
MVP
dup  16q23.1  3  77,923,068  78,596,237  673  VAT1L,  CLEC3A,  WWOX  -  +  Yes
63 ToF,  PA  dup  3p26.3  3  1,750,535  2,205,306  455  CNTN4,  CNTN4-AS2  +  +  Yes
67 ToF  dup  3p26.3  3  1,775,844  2,158,248  382  CNTN4,  CNTN4-AS2  +  +  No
71 ToF  del  10q22.3-
q23.2
1  81,446,577  89,253,430  7807  LOC650623,  LOC642361,  LOC100288974,  MBL1P,
SFTPD,  LOC219347,  C10orf57,  PLAC9,  ANXA11,
LOC439990,  MAT1A,  DYDC1,  DYDC2,  FAM213A,
TSPAN14,  SH2D4B,  NRG3,  GHITM,  C10orf99,
CDHR1,  LRIT2,  LRIT1,  RGR,  LOC170425,  FAM190B,
GRID1-AS1,  GRID1,  MIR346,  WAPAL,  OPN4,  LDB3,
BMPR1A,  MMRN2,  SNCG,  C10orf116,  AGAP11,
FAM25A,  GLUD1,  FAM35A,  FAM22A,  LOC728190,
LOC439994,  FAM22D,  LOC728218
−  +  Yes
A
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Table  1  (Continued)
ID  Type  of
CHD
CNV  Location  CNstate  Start  (bp)  Stop  (bp)  Size
(kb)
RefSeq  genes  DGV  DECIPHER  Validated
by  aCGH
72  VSD,  PA,
ASD,  TGA
dup  2p24.3-
p25.3
3  12,770  14,851,012  14,838  FAM110C,  SH3YL1,  ACP1,  FAM150B,  TMEM18,
LOC339822,  SNTG2,  TPO,  PXDN,  MYT1L,
LOC730811,  TSSC1,  TRAPPC12,  ADI1,  RNASEH1,
LOC100506054,  RPS7,  COLEC11,  ALLC,
LOC100505964,  LOC727982,  SOX11,  LOC150622,
LOC400940,  LINC00487,  CMPK2,  RSAD2,
LOC386597,  RNF144A,  LOC100506274,  LOC339788,
LINC00299,  ID2,  KIDINS220,  MBOAT2,  ASAP2,
ITGB1BP1,  CPSF3,  IAH1,  ADAM17,  YWHAQ,  TAF1B,
GRHL1,  KLF11,  CYS1,  RRM2,  C2orf48,  MIR4261,
HPCAL1,  ODC1,  SNORA80B,  NOL10,  ATP6V1C2,
PDIA6,  KCNF1,  FLJ33534,  C2orf50,  PQLC3,  ROCK2,
LINC00570,  E2F6,  GREB1,  MIR4429,  NTSR2,  LPIN1,
MIR4262,  TRIB2,  MIR3125,  LOC100506474,  FAM84A
−  +  Yes
del 4q35.1-
q35.2
1  186,464,011  190,957,473  4493  SORBS2,  TLR3,  FAM149A,  FLJ38576,  CYP4V2,
KLKB1,  F11,  LOC285441,  MTNR1A,  FAT1,
LOC339975,  ZFP42,  TRIML2,  TRIML1,  LOC401164,
HSP90AA4P,  FRG1,  LOC100288255,  FRG2
−  +  Yes
del 16p12.2  1  21,576,802  21,951,415  375  METTL9,  IGSF6,  OTOA,  RRN3P1  +  +  Yes
77 VSD,  PA,
ASD,
PLSVC
del  8p23.1  1  8,093,065  11,935,465  3842  FLJ10661,  SGK223,  CLDN23,  MFHAS1,  ERI1,
MIR4660,  PPP1R3B,  LOC157273,  TNKS,  MIR597,
LINC00599,  MIR124-1,  MSRA,  PRSS55,  RP1L1,
C8orf74,  SOX7,  PINX1,  MIR1322,  XKR6,  MIR598,
MTMR9,  SLC35G5,  TDH,  C8orf12,  FAM167A,  BLK,
LINC00208,  GATA4,  NEIL2,  FDFT1,  CTSB,  DEFB136,
DEFB135,  DEFB134,  LOC100133267,  DEFB130
−  +  PV
78 BAV,  EA,
SV
del  22q13.33  1  50,100,435  51,197,838  1097  BRD1,  LOC90834,  ZBED4,  ALG12,  CRELD2,  PIM3,
IL17REL,  MLC1,  MOV10L1,  PANX2,  TRABD,  SELO,
TUBGCP6,  HDAC10,  MAPK12,  MAPK11,  PLXNB2,
FAM116B,  PPP6R2,  SBF1,  ADM2,  MIOX,  LMF2,
NCAPH2,  SCO2,  TYMP,  ODF3B,  KLHDC7B,  SYCE3,
CPT1B,  CHKB-CPT1B,  CHKB,  LOC100144603,
MAPK8IP2,  ARSA,  SHANK3,  ACR,  RPL23AP82
−  +  PV
ID, patient identification; CHD, congenital heart disease; ASD, atrial septal defect; ToF, tetralogy of Fallot; IAA, interrupted aortic arch; TA, truncus arteriosus; VSD, ventricular septal
defect; PA, pulmonary atresia; PDA, patent ductus arteriosus; BAV, bicuspid aortic valve; PLSVC, persistent left superior vena cava; MVP, mitral valve prolapse; TGA, transposition of the
great arteries; BAV, bicuspid aortic valve; EA, ectasia of the aorta; SV, sinus of Valsalva; CNV, copy number variation; del, deletion; dup, duplication; bp, base pairs; kb, kilobases; DGV,
Database of Genomic Variants;6 DECIPHER, Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources;7 +, presence; −, absence; aCGH, array comparative
genomic hybridization (using Agilent Human Genome G3 SurePrint 8x60K Microarray); NP, not performed; PV, previously validated (detected by fluorescence in situ hybridization and/or
multiplex ligation probe amplification techniques).
A
RTICLE IN PRESS
+M
odel
8
 
Coelho
 M
olck
 M
 et
 al.
Table  2  Clinical  features  of  patients  presenting  CNVs  related  to  syndromes  with  multiple  congenital  anomalies  that  overlap  with  22q11.2  DS.
Case  8  Case  26  Case  29  Case  40  Case  71  Case  72  Case  77  Case  78  22q11.2DSa
Genomic  imbalance  del  16p11.2  del  17q12  del  5p15.1-p15.33  dup  3q26.2  del  10q22.3-q23.2  del  4q35.1-q35.2  del  8p23.1  del  22q13.33  del  22q11.2
Size of  aberration  611  kb  1.8  Mb  17.4  Mb  2.0  Mb  7.8  Mb  4.5  Mb  3.8  Mb  1.1  Mb  1.5--3.0  Mb
Gender Male  Male  Male  Female  Male  Female  Female  Male  Evenly  distributed
Age at  evaluation  7  y  11  y  1  y  2  y  3  y  39  y  5  y  10  y  56%  ≤5  y
Growth delay  +  −  +  −  −  −  −  −  NR
Congenital heart
disease
+  +  +  +  +  +  +  +  74%
Palatal abnormalities +  +  +  +  −  −  +  −  69%
Facial dysmorphisms  +  +  +  +  +  +  +  +  Common
Immunological
abnormalities
+ −  −  −  +  −  +  +  Common
Developmental  delay  −  +  +  −  +  +  +  +  70−90%
Feeding problems  −  −  −  −  −  −  −  +  30%
Hearing loss  +  +  −  −  −  −  −  −  39%
Eye abnormalities  −  −  −  −  −  −  −  −  ≥69%
Neurological
abnormalities
− −  −  −  −  −  −  −  NR
Urinary tract
anomalies
−  −  +  −  −  −  −  −  37%
Gastrointestinal
anomalies
+ −  +  −  −  −  +  −  NR
Skeletal
abnormalities
− −  −  +  +  +  +  +  NR
del, deletion; dup, duplication; kb, kilobases; Mb, megabases; y, years; +, presence; −, absence; NR, not reported; 22q11.2 DS, 22q11.2 deletion syndrome.
a McDonald-McGinn et al.2
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Table  3  Candidate  genes  for  CHD  involved  in  clinically  significant  CNVs  detected.
Gene  OMIM  Functions  Process
IRX4  606199  Sequence-specific  DNA  binding  Establishment  of  organ  orientation;  heart
development;  regulation  of  transcription;
DNA-templated
BMPR1A 601299  BMP  receptor,  RNA  polymerase  II
transcription  factor,  protein
homodimerization  and  protein
serine/threonine  kinase  activity;  ATP,
sequence-specific  DNA,  SMAD,
glycoprotein,  metal  ion  and  protein
binding;
BMP  signaling  pathway;  cardiac  conduction
system  development;  cardiac  right  ventricle,
dorsal  aorta  and  mitral  valve  morphogenesis;
heart  formation
SORBS2 616349  Cytoskeletal  adaptor  activity;  metal
ion,  poly(A)  RNA  and  protein  binding;
structural  constituent  of
cytoskeleton;  structural  constituent
of muscle
Actin  filament  organization;  biological  process;
cell adhesion;  cell  growth  involved  in  cardiac
muscle  cell  development;  cell  migration
ID2 600386  ATP,  Rho  GTPase,  metal  ion,  poly(A)
RNA  and  protein  binding;  protein
dimerization  activity
Membranous  septum  morphogenesis;
metanephros  development;  multicellular
organism  development;  natural  killer  cell
differentiation
ROCK2 604002  Rho-dependent  protein
serine/threonine  kinase,  protein
serine/threonine  kinase  and
structural  molecule  activity
Centrosome  duplication;  cortical  actin
cytoskeleton  organization;  cytokinesis;  ephrin
receptor  signaling  pathway;  negative
regulation  of  angiogenesis
E2F6 602944  DNA,  protein  and  transcription  factor
activity,  sequence-specific  DNA
binding;  transcription  corepressor
activity
Negative  regulation  of  transcription  from  RNA
polymerase  II  promoter;  regulation  of
transcription  involved  in  G1/S  transition  of
mitotic  cell  cycle;  transcription,
DNA-templated
GATA4 600576  DNA,  NFAT  protein,  RNA  polymerase  II
transcription  factor,  activating
transcription  factor,  chromatin,
co-SMAD,  enhancer  sequence-specific
DNA  and  sequence-specific  DNA
binding;  transcription  coactivator
activity;  zinc  ion  binding
Anatomical  structure  formation  involved  in
morphogenesis;  atrial  septum,  cardiac
ventricle  morphogenesis;  blood  coagulation;
cell development;  cell  growth  involved  in
cardiac  muscle  cell  development;  embryonic
heart tube  anterior/posterior  pattern
specification;  endocardial  cushion
development;  heart  looping
SOX7 612202  Protein,  transcription  factor  activity,
sequence-specific  DNA  and
transcription  regulatory  region  DNA
binding
Endoderm  formation;  negative  regulation  of
cell proliferation;  negative  regulation  of
transcription,  DNA-templated;  positive
regulation  of  cysteine-type  endopeptidase
activity  involved  in  apoptotic  process;
regulation  of  canonical  Wnt  signaling  pathway;
transcription,  DNA-templated
a
T
p
b
h
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mOMIM, Online Mendelian Inheritance In Man.8
pulmonary  atresia,  and  transposition  of  the  great  arteries.
The  4q35.1-q35.2  deleted  region  allocates  the  SORBS2  gene,
which  is  highly  expressed  in  intercalated  discs  of  normal
heart  tissues.13 The  2p24.3-p25.3  duplicated  region  harbors
the  ID2,  ROCK2, and  E2F6  genes,  which  have  roles  in  heart
development  and  are  candidate  genes  for  CHD.14--16
Case  77  showed  a  3.8  Mb  deletion  harboring  the  critical
region  of  8p23.1  deletion  syndrome;  CHD  is  the  hallmark  of
this  syndrome,  mainly  atrioventricular  septal  defects,  atrial
septal  defect,  and  pulmonary  stenosis,5 in  common  with  the
findings  of  this  patient.  In  addition,  it  has  been  observed  that
microcephaly,  facial  dysmorphisms,  developmental  delay,
c
M
d
Tnd  behavioral  problems  are  associated  with  this  syndrome.5
he  present  patient  had  VSD,  ASD,  pulmonary  atresia,  and
ersistent  left  superior  vena  cava.  This  deleted  region  har-
ors  GATA4  and  SOX7  genes,  both  transcription  factors  that
ave  roles  in  cardiac  embryogenesis.  They  have  been  sug-
ested  as  candidate  genes  for  CHD,  based  on  animal  models,
utations  reported  by  patients,  and  CNVs  studies.17,18
Case  78  presented  a  1.1  Mb  deletion  encompassing  the
ritical  region  of  22q13.33  deletion  syndrome  (Phelan-
cDermid  syndrome),  characterized  by  developmental
elay,  delayed  or  absent  speech,  and  autistic  features.27
he  present  patient  shares  developmental  and  speech  delay.
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n  addition,  less  frequently,  facial  dysmorphisms,  recurrent
nfections,  CHD,  and  difficult  feeding28 have  been  observed,
n  common  with  this  patient.  The  patient  had  BAV,  aortic
ctasia,  and  sinus  of  Valsalva.  This  deleted  region  does  not
llocate  candidate  genes  related  to  CHD,  to  date.
CNV  studies  in  patients  with  similar  phenotypes  of  well-
nown  diseases  can  contribute  to  a  better  knowledge  of
henotypes,  and  to  the  identification  of  genes  and  path-
ays  involved  in  specific  CHDs  and  other  defects.29 The
NVs  detected  in  this  study  that  were  previously  described
n  clinically  recognizable  syndromes  can  help  the  clinical
anagement  and  offer  appropriate  genetic  counseling  for
hese  patients  and  their  families.  These  findings  also  rein-
orce  the  importance  of  CMA  for  the  diagnosis.  In  addition,
wo  CNVs  herein  detected  are  potentially  related  to  CHD.
Case  35  presented  a  duplication  in  15q21.1  (993  kb),
ncluding  seven  genes,  two  of  which  should  be  highlighted.
EMA6D  plays  an  essential  role  in  heart  morphogenesis30;
BN1  operates  in  cardiac  development  and  mutations  in  this
ene  have  been  associated  with  CHD.31 This  CNV  is  described
n  four  individuals  in  DECIPHER  (286150,  250179,  260222,
78520)  who  have  this  variant  alone;  however,  none  of  them
ad  CHD.  This  CNV  was  not  detected  in  the  DGV.  The  present
atient  had  ToF,  pulmonary  atresia,  and  persistent  left  supe-
ior  vena  cava.
Case  52  presented  a  duplication  in  2p22.3  (706  kb),
ncluding  seven  genes  such  as  LTPB1, which  is  the  major
egulator  of  the  TGFB1  gene  and  acts  in  the  development
f  heart  valve.32 This  CNV  has  been  found  in  two  individuals
n  DECIPHER  (249550,  249780),  who  present  only  this  vari-
nt;  however,  without  CHD.  This  CNV  has  been  described  in
our  studies  in  the  DGV  the  (variation  8367,  variation  53694,
ariation  5203,  variation  5202).  The  present  patient  had
oF,  pulmonary  atresia,  and  ASD.
Clinically  significant  CNVs  were  identified  in  10%  of
ases,  reinforcing  that  CMA  is  a  reliable  technology  for
atients  presenting  CHD  with  extra  cardiac  anomalies  and
xclusion  of  22q11.2  DS.  There  is  an  overlap  among  the
linical  manifestations  of  various  syndromes  listed  here,
lthough  comprising  distinct  frames.  The  same  applies  to
he  phenotype  of  the  present  patients.  It  reinforces  the  com-
lex  mechanisms  involved  in  human  embryogenesis,  which
mplies  the  correct  interaction  between  genes.  As  several
ene  interaction  mechanisms  have  not  been  completely  elu-
idated,  this  study  emphasizes  the  possible  role  of  CNVs  in
HD.
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